Tucatinib clinical trials
Also written Tukysa, ONT-380, ARRY-380 and Irbinitinib.
ClinicalTrials.gov finds 72 studies for tucatinib. How that becomes 55 here
Every study that search finds has been read, to see whether and how it gives tucatinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 72Found by its intervention search · See all 72 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 67 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyNCT06828588 · Only a keyword; the study images a HER2 tracerReport a problem
- +2Give it under a name that search misses: a biosimilar’s code or a misspelling
- 73Give tucatinib to participants
- −6Observe patients on it, or give it outside a trial
- −1Compare another treatment with it
- −11Give it beside what is tested
- 55Test it: the count on this site
Get an email when these change. Save the tucatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Apr 2020 · TUKYSA · NDA 213411 (FDA, Drugs@FDA)
- European Union
- 11 Feb 2021 · Tukysa · EMEA/H/C/005263 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
55 studies that test it; most in 2023 (12)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 7 |
| 2023 | 12 |
| 2024 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 30
Seagen Inc. (11) · Seagen, a wholly owned subsidiary of Pfizer (6) · Pfizer (3) · Dana-Farber Cancer Institute (3) · Criterium, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · UNICANCER (2) · Institut Curie (2)
Often tested with
Tested in the same studies.
Trastuzumab (17) · Pertuzumab (5) · Capecitabine (4) · Trastuzumab deruxtecan (4) · Ado-Trastuzumab Emtansine (4) · Olaparib (3) · Pembrolizumab (3) · Atezolizumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Tucatinib is the comparator. A study of two new drugs counts under both.
- 1Bizrolertinib · Hoffmann-La Roche · next primary completion May 2029
New treatments tested with it · 7 most studied
New when their studies opened, with tucatinib beside them; studies of each.
- 2Zanidatamab
- 1Disitamab vedotin
- 1Mutant-selective PI3K-alpha H1047R Inhibitor OKI-219
- 1Cinrebafusp alfa
- 1Patritumab deruxtecan
- 1ALX148
- 1MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138
Reaching primary completion within a year · 10
Studies that test tucatinib.
- Nov 2026Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibPhase 2 · Carey Anders, M.D.
- Dec 2026Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseasePhase 2 · UNICANCER
- Dec 2026Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Phase 1 · Pfizer
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Dec 2026Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyPhase 2 · Sunnybrook Health Sciences Centre
- Mar 2027A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)Phase 2 · M.D. Anderson Cancer Center
- Apr 2027Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerPhase 1/2 · Jonsson Comprehensive Cancer Center
- Jun 2027Tucatinib+Trastuzumab+Eribulin in HER2+ MBCPhase 2 · Criterium, Inc.
- Jul 2027A Study of Tucatinib and Trastuzumab in People With Rectal CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerPhase 2 · SCRI Development Innovations, LLC
Studies
Open first, then newest update. How each study uses tucatinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 55
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05672524With trastuzumab before total neoadjuvant therapy in rectal cancerWritten as TucatinibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535With trastuzumab for ERBB2-altered cancers in one basket armWritten as Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)Report a problem
- Tucatinib Continuation StudyNot yet recruitingPhase 4PfizerNCT07768358Continued for people from earlier tucatinib studiesWritten as tucatinibReport a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Part of a curative-intent sequence in de novo HER2-positive breast cancerWritten as TucatinibReport a problem
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05673928With T-DM1 for brain metastases from HER2-positive tumoursWritten as TucatinibReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Added to trastuzumab and pertuzumab in one I-SPY armWritten as Tucatinib plus trastuzumab and pertuzumabReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Alone for ERBB2-altered cancers in one basket armWritten as TucatinibReport a problem
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingPhase 2SCRI Development Innovations, LLCNCT05748834With liposomal doxorubicin in HER2-positive breast cancerWritten as TucatinibReport a problem
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingPhase 2Sunnybrook Health Sciences CentreNCT06016387With trastuzumab, capecitabine and radiotherapy for leptomeningeal diseaseWritten as Tucatinib 150 MGReport a problem
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingPhase 2Institut CurieNCT07193394With trastuzumab in HER3-mutant, HER2-non-amplified breast cancerWritten as Tucatinib (ONT-380)Report a problem
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingPhase 2UNICANCERNCT05800275With capecitabine and intrathecal trastuzumab for leptomeningeal diseaseWritten as Tucatinib Oral TabletReport a problem
- Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerRecruitingPhase 2Institut CurieNCT05955170With oral etoposide and trastuzumab after earlier tucatinibReport a problem
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingPhase 1The Netherlands Cancer InstituteNCT06162559With trastuzumab and pertuzumab, without chemotherapy, before surgeryWritten as TucatinibReport a problem
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingPhase 1Jonathan RiessNCT06067776With osimertinib and cetuximab in EGFR-mutant lung cancerWritten as TucatinibReport a problem
- TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Not yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04760431One HER2 TKI option, against pertuzumab, for brain metastasesReport a problem
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651With trastuzumab and FOLFOX against standard care in colorectal cancerWritten as tucatinibReport a problem
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedPhase 2Breast Cancer Trials, Australia and New ZealandNCT04789096With pembrolizumab and trastuzumab in pretreated HER2-positive breast cancerWritten as TucatinibReport a problem
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05132582On the US labelAdded to trastuzumab and pertuzumab maintenance against placeboWritten as TucatinibReport a problem
- A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingPhase 2PfizerNCT04721977With trastuzumab and capecitabine after T-DM1Written as TucatinibReport a problem
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04579380With trastuzumab in solid tumours with HER2 alterationsWritten as tucatinibReport a problem
See all 55 studies that test tucatinib →
Behind its US label · 3 — the studies the FDA label of TUKYSA describes
From the Clinical Studies section of TUKYSA (2026-10), as openFDA has it. A study the site does not hold is left out.
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedPhase 2Seagen Inc.NCT02614794Report a problem
- Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedPhase 2Seagen Inc.NCT03043313Report a problem
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05132582Report a problem
Tested on its own · 6 — no other medicine in its arm
- Tucatinib Continuation StudyNot yet recruitingPhase 4PfizerNCT07768358Continued for people from earlier tucatinib studiesWritten as tucatinibReport a problem
- Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingPhase 1PfizerNCT05382364Safety and blood levels in Chinese patientsWritten as TucatinibReport a problem
- A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05892068Before surgery for brain metastases, to measure brain penetrationWritten as TucatinibReport a problem
- A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Seagen Inc.NCT03914755Blood levels in healthy Japanese and Caucasian peopleWritten as TucatinibReport a problem
- A Safety Study of Tucatinib in Healthy and Hepatically-Impaired SubjectsCompletedPhase 1Seagen Inc.NCT03722823Blood levels with liver impairmentWritten as TucatinibReport a problem
- A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy ParticipantsCompletedPhase 1Cascadian Therapeutics Inc.NCT03758339How the body absorbs and clears radiolabelled tucatinibWritten as tucatinibReport a problem
Tested with established drugs · 16 — they are given beside it
- TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Not yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04760431One HER2 TKI option, against pertuzumab, for brain metastasesReport a problem
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05132582On the US labelAdded to trastuzumab and pertuzumab maintenance against placeboWritten as TucatinibReport a problem
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04579380With trastuzumab in solid tumours with HER2 alterationsWritten as tucatinibReport a problem
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT03975647Added to T-DM1 against placebo in HER2-positive breast cancerWritten as tucatinibReport a problem
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingPhase 2Carey Anders, M.D.NCT05323955Added to maintenance HER2 therapy after brain metastasis treatmentWritten as TucatinibReport a problem
- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04457596Added to T-DM1 for residual HER2-positive breast cancerWritten as TucatinibReport a problem
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04430738With trastuzumab and chemotherapy or pembrolizumab in GI cancersWritten as tucatinibReport a problem
- Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedPhase 2/3Seagen Inc.NCT04499924With trastuzumab added to ramucirumab and paclitaxel in gastric cancerWritten as tucatinibReport a problem
- Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedPhase 2Seagen Inc.NCT03043313On the US labelWith trastuzumab or alone in HER2-positive colorectal cancerWritten as TucatinibReport a problem
- ARRY-380 + Trastuzuamab for Breast w/ Brain MetsCompletedPhase 1Dana-Farber Cancer InstituteNCT01921335Dose finding with trastuzumab in breast cancer brain metastasesWritten as ARRY-380 Twice Daily DosageReport a problem
- Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerCompletedPhase 1/2University of Colorado, DenverNCT03054363With palbociclib and letrozole in HR-positive, HER2-positive breast cancerWritten as Tucatinib in Combination with Palbociclib and LetrozoleReport a problem
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedPhase 2Seagen Inc.NCT02614794On the US labelAdded to capecitabine and trastuzumab against placeboWritten as tucatinibReport a problem
- A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedPhase 1Seagen Inc.NCT01983501Dose finding with T-DM1 in HER2-positive breast cancerWritten as Tucatinib (ONT-380)Report a problem
- A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerCompletedPhase 1Seagen Inc.NCT02025192Dose finding with capecitabine, trastuzumab or bothWritten as TucatinibReport a problem
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedPhase 1Seagen Inc.NCT03723395Drug interactions with enzyme inhibitors, inducers and probe drugsWritten as tucatinibReport a problem
- Effects of Tucatinib on Cardiac Repolarization in Healthy ParticipantsCompletedPhase 1Seagen Inc.NCT03777761Its effect on heart rhythm in healthy peopleWritten as tucatinibReport a problem
Tested in a combination · 33 — another drug in the study is under test too
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05672524With trastuzumab before total neoadjuvant therapy in rectal cancerWritten as TucatinibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535With trastuzumab for ERBB2-altered cancers in one basket armWritten as Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)Report a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Part of a curative-intent sequence in de novo HER2-positive breast cancerWritten as TucatinibReport a problem
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05673928With T-DM1 for brain metastases from HER2-positive tumoursWritten as TucatinibReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Added to trastuzumab and pertuzumab in one I-SPY armWritten as Tucatinib plus trastuzumab and pertuzumabReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Alone for ERBB2-altered cancers in one basket armWritten as TucatinibReport a problem
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingPhase 2SCRI Development Innovations, LLCNCT05748834With liposomal doxorubicin in HER2-positive breast cancerWritten as TucatinibReport a problem
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingPhase 2Sunnybrook Health Sciences CentreNCT06016387With trastuzumab, capecitabine and radiotherapy for leptomeningeal diseaseWritten as Tucatinib 150 MGReport a problem
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingPhase 2Institut CurieNCT07193394With trastuzumab in HER3-mutant, HER2-non-amplified breast cancerWritten as Tucatinib (ONT-380)Report a problem
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingPhase 2UNICANCERNCT05800275With capecitabine and intrathecal trastuzumab for leptomeningeal diseaseWritten as Tucatinib Oral TabletReport a problem
- Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerRecruitingPhase 2Institut CurieNCT05955170With oral etoposide and trastuzumab after earlier tucatinibReport a problem
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingPhase 1The Netherlands Cancer InstituteNCT06162559With trastuzumab and pertuzumab, without chemotherapy, before surgeryWritten as TucatinibReport a problem
- Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingPhase 1Jonathan RiessNCT06067776With osimertinib and cetuximab in EGFR-mutant lung cancerWritten as TucatinibReport a problem
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651With trastuzumab and FOLFOX against standard care in colorectal cancerWritten as tucatinibReport a problem
- Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedPhase 2Breast Cancer Trials, Australia and New ZealandNCT04789096With pembrolizumab and trastuzumab in pretreated HER2-positive breast cancerWritten as TucatinibReport a problem
- A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingPhase 2PfizerNCT04721977With trastuzumab and capecitabine after T-DM1Written as TucatinibReport a problem
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingPhase 2Criterium, Inc.NCT05458674With eribulin and trastuzumab in pretreated breast cancerWritten as TucatinibReport a problem
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05319873With ribociclib and trastuzumab, against chemotherapy before surgeryWritten as TucatinibReport a problem
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04539938With trastuzumab deruxtecan in HER2-positive breast cancerWritten as tucatinibReport a problem
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingPhase 1/2Criterium, Inc.NCT05230810With alpelisib in PIK3CA-mutant HER2-positive breast cancerWritten as TucatinibReport a problem
Showing 20 of 33. See all 33 →
Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests
Tested with tucatinib: Capecitabine 2 · margetuximab 1
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448In every armBackbone with chemotherapy; zanidatamab is added and its dose foundWritten as TucatinibReport a problem
- Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnPhase 2MedSIRNCT05227131In every armBackbone with capecitabine; margetuximab takes trastuzumab's placeWritten as TucatinibReport a problem
Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with tucatinib: zanidatamab 2 · disitamab vedotin 1 · Mutant-selective PI3K-alpha H1047R Inhibitor OKI-219 1 · cinrebafusp alfa 1 · patritumab deruxtecan 1 · ALX148 1 · MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138 1
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Partner of new patritumab deruxtecan in one armWritten as TucatinibReport a problem
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Partner of zanidatamab in one platform armWritten as TucatinibReport a problem
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT06157892In every armPartner of new disitamab vedotin in breast and gastric cancerWritten as tucatinibReport a problem
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingPhase 1OnKure, Inc.NCT06239467Partner of new OKI-219 with trastuzumab in one partWritten as TucatinibReport a problem
- Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersCompletedPhase 1Jazz PharmaceuticalsNCT02892123In every armPartner of new zanidatamab in one cohortWritten as TucatinibReport a problem
- Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaActive, not recruitingPhase 2Pieris Pharmaceuticals, Inc.NCT05190445Partner of new cinrebafusp alfa in HER2-low gastric cancerReport a problem
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedPhase 1/2Silverback TherapeuticsNCT05091528Partner of new SBT6050 with trastuzumabWritten as tucatinibReport a problem
Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 1 — a test or a strategy chooses among drugs
As the comparator · 1 — what is tested is compared with tucatinib
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingPhase 2/3Hoffmann-La RocheNCT07413939Comparator for new brain-penetrant RO7771950Written as TucatinibReport a problem
Observed · 6 — patients on it are followed, or it is given outside a trial
- A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06839547One of the newer drugs observed with brain radiotherapyReport a problem
- GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingRecruitingFondazione OncotechNCT07583485Real-world use with capecitabine and trastuzumab in ItalyReport a problem
- Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.CompletedPfizerNCT06961331Real-world outcomes after trastuzumab deruxtecanWritten as TucatinibReport a problem
- Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletediOMEDICO AGNCT05253911Real-world use with trastuzumab and capecitabineWritten as TUKYSA®Report a problem
- Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved for marketingSeagen, a wholly owned subsidiary of PfizerNCT04220203Access before approval, with capecitabine and trastuzumabWritten as TucatinibReport a problem
- Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerNo longer availableSeagen Inc.NCT03424473Expanded access for HER2-positive metastatic breast cancerWritten as TucatinibReport a problem
Codes
What other systems call tucatinib · ClinicalTrials.gg INT001276
- MeSH (NLM) C000705452tucatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 234248D0HHTUCATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2361285One source FDA
- Wikidata Q25100690tucatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77896TucatinibOne source FDA
- DrugBank DB11652One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705452 | tucatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 234248D0HH | TUCATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2361285 | — | One source FDA |
| Wikidata | Q25100690 | tucatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77896 | Tucatinib | One source FDA |
| DrugBank | DB11652 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.